Threshold adjusted vagus nerve stimulation after asphyxial cardiac arrest results in neuroprotection and improved survival.
Cardiac arrest
Ischemia-reperfusion injury
Neuroprotection
Vagus nerve stimulation
Journal
Bioelectronic medicine
ISSN: 2332-8886
Titre abrégé: Bioelectron Med
Pays: England
ID NLM: 101660849
Informations de publication
Date de publication:
20 Jul 2022
20 Jul 2022
Historique:
received:
30
05
2022
accepted:
24
06
2022
entrez:
19
7
2022
pubmed:
20
7
2022
medline:
20
7
2022
Statut:
epublish
Résumé
Vagus nerve stimulation (VNS) has shown therapeutic potential in a variety of different diseases with many ongoing clinical trials. The role of VNS in reducing ischemic injury in the brain requires further evaluation. Cardiac arrest (CA) causes global ischemia and leads to the injury of vital organs, especially the brain. In this study, we investigated the protective effects of customized threshold-adjusted VNS (tVNS) in a rat model of CA and resuscitation. Sprague-Dawley rats underwent 12 min asphyxia-CA followed by resuscitation. Rats were assigned to either post-resuscitation tVNS for 2 h or no-tVNS (control). tVNS was applied by electrode placement in the left cervical vagus nerve. To optimize a threshold, we used animal's heart rate and determined a 15-20% drop from baseline levels as the effective and physiological threshold for each animal. The primary endpoint was 72 h survival; secondary endpoints included neurological functional recovery, reduction in brain cellular injury (histopathology), cardiac and renal injury parameters (troponin I and creatinine levels, respectively). In comparison to the control group, tVNS significantly improved 72 h survival and brain functional recovery after 12 minutes of CA. The tVNS group demonstrated significantly reduced numbers of damaged neurons in the CA1 hippocampal region of the brain as compared to the control group. Similarly, the tVNS group showed decreased trend in plasma troponin I and creatinine levels as compared to the control group. Our findings suggest that using tVNS for 2 h after 12 minutes of CA attenuates ischemia neuronal cell death, heart and kidney damage, and improves 72 h survival with improved neurological recovery.
Sections du résumé
BACKGROUND
BACKGROUND
Vagus nerve stimulation (VNS) has shown therapeutic potential in a variety of different diseases with many ongoing clinical trials. The role of VNS in reducing ischemic injury in the brain requires further evaluation. Cardiac arrest (CA) causes global ischemia and leads to the injury of vital organs, especially the brain. In this study, we investigated the protective effects of customized threshold-adjusted VNS (tVNS) in a rat model of CA and resuscitation.
METHODS
METHODS
Sprague-Dawley rats underwent 12 min asphyxia-CA followed by resuscitation. Rats were assigned to either post-resuscitation tVNS for 2 h or no-tVNS (control). tVNS was applied by electrode placement in the left cervical vagus nerve. To optimize a threshold, we used animal's heart rate and determined a 15-20% drop from baseline levels as the effective and physiological threshold for each animal. The primary endpoint was 72 h survival; secondary endpoints included neurological functional recovery, reduction in brain cellular injury (histopathology), cardiac and renal injury parameters (troponin I and creatinine levels, respectively).
RESULTS
RESULTS
In comparison to the control group, tVNS significantly improved 72 h survival and brain functional recovery after 12 minutes of CA. The tVNS group demonstrated significantly reduced numbers of damaged neurons in the CA1 hippocampal region of the brain as compared to the control group. Similarly, the tVNS group showed decreased trend in plasma troponin I and creatinine levels as compared to the control group.
CONCLUSIONS
CONCLUSIONS
Our findings suggest that using tVNS for 2 h after 12 minutes of CA attenuates ischemia neuronal cell death, heart and kidney damage, and improves 72 h survival with improved neurological recovery.
Identifiants
pubmed: 35854394
doi: 10.1186/s42234-022-00092-0
pii: 10.1186/s42234-022-00092-0
pmc: PMC9297561
doi:
Types de publication
Journal Article
Langues
eng
Pagination
10Subventions
Organisme : NIGMS NIH HHS
ID : R35 GM118182
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Resuscitation. 2008 Mar;76(3):431-42
pubmed: 17936492
Lancet. 2021 Apr 24;397(10284):1545-1553
pubmed: 33894832
Front Pediatr. 2017 Aug 16;5:174
pubmed: 28861407
J Am Soc Nephrol. 2008 Jul;19(7):1360-70
pubmed: 18385426
Resuscitation. 2009 Oct;80(10):1114-8
pubmed: 19625120
Neuropsychopharmacology. 2006 Jul;31(7):1345-55
pubmed: 16641939
Antioxid Redox Signal. 2010 Jan;12(1):125-69
pubmed: 19624272
Resuscitation. 1995 Jun;29(3):249-63
pubmed: 7667556
Circ Res. 2004 Jun 25;94(12):1543-53
pubmed: 15217919
Crit Care. 2009;13(5):R168
pubmed: 19874577
Shock. 2013 Jan;39(1):39-44
pubmed: 23247120
J Intensive Care Med. 2020 Mar;35(3):219-224
pubmed: 30526209
J Am Heart Assoc. 2018 Jun 29;7(13):
pubmed: 29959138
Sci Rep. 2020 Jul 28;10(1):12626
pubmed: 32724110
Front Med (Lausanne). 2021 May 18;8:636651
pubmed: 34084772
Cell Calcium. 2004 Sep-Oct;36(3-4):221-33
pubmed: 15261478
J Neural Eng. 2021 Jun 04;18(4):
pubmed: 34036940
Redox Biol. 2015 Dec;6:524-551
pubmed: 26484802
Resuscitation. 2010 Jan;81(1):93-9
pubmed: 19926192
Front Aging Neurosci. 2014 Nov 27;6:322
pubmed: 25505884
Shock. 2018 Jun;49(6):698-703
pubmed: 28800036
Sci Rep. 2020 Jun 8;10(1):9221
pubmed: 32513973
Neurocrit Care. 2019 Jun;30(3):572-580
pubmed: 30382532
Brain Stimul. 2020 Nov - Dec;13(6):1617-1630
pubmed: 32956868
Front Cardiovasc Med. 2021 Apr 26;8:648910
pubmed: 33981734
Crit Care Med. 2019 Jun;47(6):e461-e469
pubmed: 30908312
PLoS One. 2015 Mar 19;10(3):e0120914
pubmed: 25789868
J Clin Invest. 2007 Feb;117(2):289-96
pubmed: 17273548
N Engl J Med. 2021 Jun 17;384(24):2283-2294
pubmed: 34133859
Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):8284-9
pubmed: 27382171
J Clin Invest. 2016 May 2;126(5):1939-52
pubmed: 27088805
Mol Med. 2021 Oct 24;27(1):135
pubmed: 34689738
Cerebrovasc Dis. 2007;23(4):260-6
pubmed: 17199083
J Clin Neurophysiol. 2001 Sep;18(5):429-33
pubmed: 11709648
Proc Natl Acad Sci U S A. 2021 Mar 23;118(12):
pubmed: 33737395
World J Emerg Med. 2021;12(4):309-316
pubmed: 34512829
Neuroreport. 2021 Jun 9;32(9):783-791
pubmed: 33994524
Nature. 2000 May 25;405(6785):458-62
pubmed: 10839541
J Cell Mol Med. 2017 Jan;21(1):58-71
pubmed: 27491814
Int Rev Cell Mol Biol. 2012;298:229-317
pubmed: 22878108